Results of the SWOG S0500 Trial
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.
Clinical Pearls
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer. Results of the trial were presented at the 2013 San Antonio Breast Cancer Symposium.
- The trial set out to determine whether CTC levels could be used to guide the frontline treatment of metastatic breast cancer
- It was hypothesized that those patients who maintained a high level of CTCs would do badly
- Patients with low CTC levels before and after chemotherapy did best
- Patients with elevated CTC levels before chemotherapy but lower levels after chemotherapy did moderately well
- Patients with elevated CTC levels before and after chemotherapy did poorly
- This trial demonstrated how dramatic the differences were in prognosis amongst the three groups
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
